Cas no 139264-17-8 (Zolmitriptan)

Zolmitriptan is a selective serotonin receptor agonist, primarily targeting the 5-HT1B/1D receptors, and is used for the acute treatment of migraine attacks. Its mechanism involves constricting cranial blood vessels and inhibiting pro-inflammatory neuropeptide release, thereby alleviating migraine symptoms. Zolmitriptan is available in oral, nasal spray, and orally disintegrating tablet formulations, offering flexibility in administration. It demonstrates rapid absorption, with onset of action typically within 15–30 minutes for nasal spray formulations. The compound exhibits good bioavailability and is metabolized primarily via CYP1A2. Clinical studies support its efficacy in reducing migraine pain and associated symptoms, such as photophobia and phonophobia, with a favorable tolerability profile in most patients.
Zolmitriptan structure
Zolmitriptan structure
Product Name:Zolmitriptan
CAS No:139264-17-8
MF:C16H21N3O2
MW:287.356843709946
MDL:MFCD00871503
CID:64586
PubChem ID:60857
Update Time:2025-11-01

Zolmitriptan Chemical and Physical Properties

Names and Identifiers

    • Zolmitriptan
    • (4r)-4-[[3-(2-dimethylaminoethyl)-1h-indol-5-yl]methyl]oxazolidin-2-one
    • (S)-4-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl-2-oxazolidinone
    • ZOLMITRIFTAN
    • (S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone
    • (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one
    • 311C90
    • BW-311C90
    • (4S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
    • (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone
    • Zomig
    • Zomigoro
    • Zomigon
    • Flezol
    • Zomig-ZMT
    • Zomig ZMT
    • Zomig Nasal Spray
    • zolmitriptanum
    • AscoTopand
    • AscoTop
    • Zolmitriptan (Zomig)
    • 2FS66TH3YW
    • 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
    • C16H21N3O2
    • (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazol
    • ZOLMITRIPTANE
    • Assists Mi Qu Pu Tanzania
    • Zolmitriptan (150 mg)
    • (4R)-4-({3-[2-(diMethylaMino)ethyl]-1H-indol-5-yl}Methyl)-1,3-oxazolidin-2-one
    • ZolMitriptan(ZoMig)
    • ZolMitriptan API
    • Tox21_111455_1
    • ZOLMITRIPTAN [VANDF]
    • SR-05000001693-1
    • SBI-0206762.P001
    • HY-B0229
    • (4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl-2-oxazolidinone
    • SPECTRUM1505281
    • 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)-
    • Zolmitriptan RapidFilm
    • (S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one
    • 2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-, (4S)-
    • ZOLMITRIPTAN [MI]
    • (S)-4-[[3-[2-(Dimethylamino)ethyl]indol-5-yl]methyl]-2-oxazolidinone
    • 4-((3-(2-dimethylaminoethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one
    • Zomig (TN)
    • ZOLMITRIPTAN [EP MONOGRAPH]
    • Spectrum2_000728
    • (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
    • (4S)-4-((3-(2-(Dimethylamino)ethyl) -1H-indol-5-yl)methyl)-2-oxazolidinone
    • SW197762-2
    • SR-05000001693
    • Cvt-427
    • NCGC00263884-08
    • D00415
    • Q218820
    • 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-,(S)-
    • C07218
    • ZOLMITRIPTAN (MART.)
    • EN300-18567396
    • Pharmakon1600-01505281
    • HMS1922B04
    • ZOLMITRIPTAN [JAN]
    • Zolmitriptan [USAN:INN:BAN]
    • CHEBI:10124
    • AKOS015850706
    • (s)-4-{3-[2-(dimethylamino)ethyl]-1h-indol-5-ylmethyl}oxazolidin-2-one
    • ULSDMUVEXKOYBU-ZDUSSCGKSA-N
    • ZOLMITRIPTAN [MART.]
    • zipton
    • Zolmitriptan (JAN/USP/INN)
    • 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
    • Tox21_111455
    • Z0024
    • DTXSID8045933
    • (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
    • HMS2235I22
    • DTXCID6025933
    • ZOLMITRIPTAN (USP MONOGRAPH)
    • (S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-1,3-oxazolidin-2-one
    • ZOLMITRIPTAN (USP-RS)
    • BDBM50033383
    • CAS-139264-17-8
    • Zolmiptriptan
    • NSC760383
    • HMS2093O14
    • NSC-760383
    • SCHEMBL33336
    • MLS001424172
    • 139264-25-8
    • HMS2052K17
    • 311-C-90
    • (4S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-1,3-oxazolidin-2-one
    • AB00698244_06
    • (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
    • BZ164590
    • MLS000758208
    • BW-311C90;311C90
    • NCGC00263884-03
    • ZOLMITRIPTAN (EP MONOGRAPH)
    • HB1801
    • s1649
    • NC00382
    • HMS3714H11
    • Zolmitriptan [USAN]
    • KS-5072
    • SPBio_000656
    • CHEMBL1185
    • HMS3884A06
    • Zolmitriptan, United States Pharmacopeia (USP) Reference Standard
    • ZMT
    • ZOLMITRIPTAN [INN]
    • (S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
    • Rapimelt
    • NSC 760383
    • BCP10513
    • Zolmitriptan OD
    • NCGC00263884-02
    • ZOLMITRIPTAN [USP-RS]
    • zominat
    • 139264-17-8
    • ZOLMITRIPTAN [USP MONOGRAPH]
    • N02CC03
    • MFCD00871503
    • Zolmitriptan, >=98% (HPLC)
    • ZOLMITRIPTAN [ORANGE BOOK]
    • CCG-38993
    • (S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H -indol-3-yl]ethylamine
    • (S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine
    • (4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone
    • ZOLMITRIPTAN [WHO-DD]
    • UNII-2FS66TH3YW
    • BIDD:GT0040
    • GTPL60
    • (S) -N,N-Dimethyl-2- [5- (2-oxo-1,3-oxazolidin-4-ylmethyl) -1H -indol-3-yl]ethylamine
    • AB00698244-05
    • DB00315
    • J-007257
    • SMR000449310
    • NCGC00095155-01
    • (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
    • BRD-K54314721-001-10-2
    • BRD-K54314721-001-09-4
    • MDL： MFCD00871503
    • Inchi： 1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
    • InChI Key： ULSDMUVEXKOYBU-ZDUSSCGKSA-N
    • SMILES： O1C(N[C@H](C1)CC1C=CC2=C(C=1)C(=CN2)CCN(C)C)=O

Computed Properties

  • Exact Mass: 287.16300
  • Monoisotopic Mass: 287.163
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 3
  • Heavy Atom Count: 21
  • Rotatable Bond Count: 5
  • Complexity: 375
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 1
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 57.4
  • XLogP3: 2.2

Experimental Properties

  • Color/Form: Powder
  • Density: 1.217
  • Melting Point: 136.0 to 140.0 deg-C
  • Boiling Point: 563.3°C at 760 mmHg
  • Flash Point: 294.5 °C
  • Refractive Index: 1.619
  • Solubility: Soluble in DMSO at 5mg/ml
  • PSA: 57.36000
  • LogP: 2.25170
  • Merck: 10189
  • pka: 9.64(at 25℃)
  • Specific Rotation: -3° to -9° (c=1, MeOH)
  • λmax: 225(lit.)
  • Sensitiveness: Sensitive to heat

Zolmitriptan Security Information

Zolmitriptan Customs Data

  • HS CODE：2934999090
  • Customs Data：

    China Customs Code:

    2934999090

    Overview:

    2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to

    Summary:

    2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Zolmitriptan Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Fluorochem
036593-1g
S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one
 139264-17-8 97%
1g
 ￡64.00 2022-03-01
Fluorochem
036593-25g
S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one
 139264-17-8 97%
25g
 ￡1487.00 2022-03-01
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
Z0024-1G
Zolmitriptan
 139264-17-8 >98.0%(T)(HPLC)
1g
 ￥465.00 2024-04-17
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
Z129649-200mg
Zolmitriptan
 139264-17-8 ≥98%(HPLC)
200mg
 ￥70.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
Z129649-250mg
Zolmitriptan
 139264-17-8 ≥98%(HPLC)
250mg
 ￥72.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
Z129649-25g
Zolmitriptan
 139264-17-8 ≥98%(HPLC)
25g
 ￥3696.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
Z129649-5g
Zolmitriptan
 139264-17-8 ≥98%(HPLC)
5g
 ￥924.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
Z129649-1g
Zolmitriptan
 139264-17-8 ≥98%(HPLC)
1g
 ￥231.90 2023-08-31
AstaTech
47224-1/G
ZOLMITRIPTAN
 139264-17-8 97%
1g
 $47 2023-09-17
AstaTech
47224-5/G
ZOLMITRIPTAN
 139264-17-8 97%
5g
 $113 2023-09-17

Zolmitriptan Production Method

Zolmitriptan Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:139264-17-8)佐米曲普坦
Order Number:LE2599774
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:41
Price ($):discuss personally

Zolmitriptan Spectrogram

13C NMR
13C NMR
1H NMR 300 MHz DMSO
1H NMR
MS-MS
MS-MS

Zolmitriptan Related Literature

Additional information on Zolmitriptan

Introduction to Zolmitriptan (CAS No. 139264-17-8) and Its Role in Modern Medicine

Zolmitriptan, a compound with the chemical identifier CAS No. 139264-17-8, is a highly specialized pharmaceutical agent that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound, belonging to the class of selective serotonin receptor agonists, is primarily utilized for its potent effects on the treatment of migraines, a condition that affects millions globally. The molecular structure of Zolmitriptan is meticulously designed to interact with specific neurological pathways, offering a targeted approach to alleviate the debilitating symptoms associated with migraines.

The development of Zolmitriptan represents a significant advancement in the management of migraines, leveraging cutting-edge research in neuropharmacology. Its efficacy lies in its ability to bind selectively to 5-HT1B and 5-HT1D receptors, primarily located in the trigeminal nerve system. This binding action leads to vasoconstriction of cranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, which are key factors in migraine pathophysiology. The precision of Zolmitriptan’s mechanism of action underscores its importance as a therapeutic option for patients suffering from this chronic neurological condition.

Recent studies have further elucidated the pharmacokinetic profile of Zolmitriptan, highlighting its rapid absorption and onset of action when administered orally or intranasally. This characteristic makes it an attractive choice for patients seeking immediate relief from acute migraine episodes. Additionally, research has explored the potential benefits of Zolmitriptan in combination therapies, suggesting that its synergistic effects with other anti-migraine agents could enhance overall treatment outcomes.

The safety profile of Zolmitriptan has been extensively evaluated through numerous clinical trials, which have demonstrated its generally well-tolerated nature when used as directed. Common side effects include nausea, dizziness, and muscle tightness, but these are typically mild and transient. However, as with any pharmaceutical agent, careful consideration must be given to individual patient factors such as pre-existing conditions and concomitant medications to ensure optimal safety and efficacy.

In the realm of drug discovery and development, Zolmitriptan serves as an exemplary model for designing molecules that exhibit high selectivity and potency. Its chemical structure has been optimized through rational drug design principles, incorporating features that enhance binding affinity while minimizing off-target effects. This approach not only contributes to the therapeutic success of Zolmitriptan but also provides valuable insights for the development of novel treatments for other neurological disorders.

The impact of Zolmitriptan extends beyond its primary use in migraine treatment; it has also sparked interest in its potential applications in other neurological conditions. Preliminary research has investigated its role in alleviating symptoms associated with cluster headaches and tension-type headaches, suggesting that Zolmitriptan may have broader therapeutic implications. These exploratory studies highlight the importance of continued research into the multifaceted applications of this compound.

As our understanding of neurological disorders evolves, so does our appreciation for agents like Zolmitriptan that offer targeted relief. The ongoing investigation into its mechanisms of action and potential new uses ensures that it remains at the forefront of migraine treatment options. For healthcare professionals managing patients with migraines, Zolmitriptan represents a reliable and effective tool in their therapeutic arsenal.

The future development of Zolmitriptan-based therapies is likely to be influenced by advancements in biotechnology and pharmacogenomics. Personalized medicine approaches could enable more precise dosing regimens based on individual genetic profiles, further enhancing patient outcomes. Additionally, the exploration of novel delivery systems may expand the versatility of Zolmitriptan formulations, offering patients more convenient and effective treatment options.

In conclusion, Zolmitriptan (CAS No. 139264-17-8) stands as a testament to the progress made in neuropharmacology through targeted drug design and rigorous clinical evaluation. Its role in treating migraines has been well-established, but its potential extends to other neurological applications. As research continues to uncover new insights into its pharmacological properties, Zolmitriptan is poised to remain a cornerstone in the management of migraines and potentially other related conditions.

139264-17-8 (Zolmitriptan) Related Products

Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:139264-17-8)佐米曲普坦
LE2599774
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email